This page has been robot translated, sorry for typos if any. Original content here.

Attention! Information is for reference only!
Before taking, be sure to consult a doctor!
SITE ONLY DIRECTORY. NOT A PHARMACY! We do not sell medicines! None!

Medication Description: Rifatiroin (Rifathyroinum)

RIFATHYROIN (Rifathyroinum).

Pyroglutamyl-histidyl-prolinamide (tripeptide).

Synonyms: Tyroliberin, Hirtonin, Protirelin, Relefact TRH, Thypinone, Thyrefact, Thyroliberin, Tiregan, and others.

White or white with a faint yellowish tint amorphous powder. Soluble in water and alcohol.

Tyroliberin (rifatiroin) is one of the main releasing factors of the hypothalamus. It promotes the release of thyroid stimulating hormone pituitary, i.e. is a releasing factor for thyroid stimulating hormone. Along with this, tiroliberin has a multifaceted effect on the body. It stimulates the secretion of prolactin, has antidepressant activity.

The main use of thyroliberin (rifatiroin) is as a means of diagnosing various forms of hypothyroidism, as well as the state of the hypothalamic-pituitary-thyroid system in various endocrine diseases; it is also used to determine the pituitary reserve of prolactin in women with hypo- and agalactia (no milk secretion) and endocrine disorders.

Injected intravenously in a single dose at a dose of 500 μg (0.5 mg). Before the introduction and after 15; 30 and 120 minutes after the administration, the content of thyroid-stimulating hormone and prolactin in the blood is determined.

After the introduction of rifatiroin after 1 - 2 minutes nausea, fever, dizziness, passing independently.

There is evidence of the use of rifatiroin for the diagnosis of disorders of the functions of the hypothalamic-pituitary-thyroid system and for monitoring therapy with thyroid drugs by intranasal administration of rifatiroin (application of 1000 μg of small drops on the nasal mucosa).

In connection with the psychotropic activity of tyroliberin, its effect on alcohol withdrawal syndrome has been studied with positive results. The drug was administered intravenously at a dose of 200 μg.

The use of rifatiroin is contraindicated in pregnancy.

Form release: in ampoules containing 500 μg of dry drug. Before use, dilute 500 µg in 2 ml of sterile water for injection or isotonic sodium chloride solution.

Storage: List B. In the dark place at a temperature of +4 C.